MR Solutions

Our new staff looks forward to meeting you at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in booth 1725. Starting today at 6 p.m. Fabrice Chaumard, Nicky Doughty and Jordan Noble will assist our new recruits for technical questions!

Congratulations to the authors of this week's Publication Spotlight!
Fei Wang, Xiangyu Zhang, Yang Liu, Zhe Li, Ruixue Wei, Yan Zhang, Ruiyi Zhang, Suliman Kahn, V. Wee Yong, Mengzhou Xue.

We studied the impact of Ozanimod on neuroprotection in an experimental mouse model of ICH. Ozanimod was administered by gavage 2 h after surgery and once a day thereafter until sacrifice. The Ozanimod treatment improved neurobehavioral deficits and decreased weight loss after ICH. Ozanimod significantly reduced the density of activated microglia and infiltrated neutrophils in the perihematoma region. Furthermore, Ozanimod reduced hematoma volume and water content of the ICH brain. The results of TUNEL staining indicate that Ozanimod mitigated brain cell death. The quantitative data of Evans blue (EB) staining showed that Ozanimod reduced EB dye leakage. Overall, Ozanimod reduces the destruction of the BBB and exert neuroprotective roles following ICH in mice.

The data was acquired on an MRS*DRYMAG 4.7T system at The University of Zhengzhou. The article was published in Frontiers in Nuclear Medicine in 2022.

The publication is available at: https://www.frontiersin.org/articles/10.3389/fnmol.2022.927150/full

Congratulations to the authors of this week's Publication Spotlight!
Jamie Zagozewski, Ghazaleh Shahriary, Ludivine Morrison, Margaret Stromecki, Agnes Fresnoza, Gareth Palidwor, Christopher Porter, Antoine Forget, Olivier Ayrault, Cynthia Hawkins, Jennifer Chan, Olivier Saulnier, Maria Vladoiu, Michael Taylor, Vijay Ramaswamy, Tamra Werbowetski-Ogilvie

OTX2 is a potent oncogene that promotes tumour growth in Group 3 medulloblastoma, via not-well characterized mechanisms. This publication shows an extensive multiomic analysis to identify an OTX2 regulatory network that controls Group 3 medulloblastoma cell fate. One of these involves an increase in the expression of neurodevelopmental transcription factors including PAX3 and PAX6. Expression of PAX3 and PAX6 is significantly lower in Group 3 medulloblastoma patients and is correlated with reduced survival, yet only PAX3 inhibits self-renewal in vitro and increases survival in vivo. Identification of mTORC1 signalling as a downstream effector of OTX2-PAX3 reveals roles for protein synthesis pathways in regulating Group 3 medulloblastoma pathogenesis.

The data was acquired on a MRS*DRYMAG 7T with a clip-on PET system at the university of Manitoba. The article was published in Nature Communications in 2020.
The publication is available at: https://doi.org/10.1093/neuonc/noz175.804

Congratulations to the authors of this week's Publication Spotlight!
Sadi Loai, Beiping Qiang, Michael A. Laflamme and Hai-Ling Margaret Cheng

This study aimed to use blood-pool MRI to assess how the heart's microvascular system responds to changes in blood gas levels, specifically looking for differences between male and female subjects. The research involved healthy rats exposed to normoxia and hypercapnia while undergoing MRI scans and laser Doppler perfusion measurements. Results showed that female rats exhibited myocardial vasodilation during hypercapnia, while males did not show significant changes. Both sexes experienced vasoconstriction upon returning to normoxia. The study concluded that blood-pool MRI is effective in detecting these responses and highlighted sex-related differences in how the heart's microcirculation reacts to mild changes in blood gas levels, which could have implications for understanding cardiovascular function and dysfunction.

The data was acquired on a MRS*DRYMAG 3T system at the University of Toronto. The article was published in Frontiers in Cardiovascular Medicine late last year.

The publication is available at: www.doi.org/10.3389/fcvm.2023.1216587